10 Micro-Cap Healthcare Stocks Insiders Are Buying
Yahoo FinanceApr 14 15:00 ET
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested
BenzingaApr 12 08:36 ET
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
TipRanksApr 8 11:05 ET
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
By Chris Wack Palatin Technologies shares were up 27% to $2.24 after the company said it saw positive topline results for its Phase 3 pivotal clinical trial evaluating the safety and efficacy of PL96
WSJApr 8 10:46 ET
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in
BenzingaApr 8 10:02 ET
Palatin Stock Jumps 16% on Positive Phase 3 Data for Eye Drug
Seeking AlphaApr 8 09:49 ET
Microstrategy, Apartment Income REIT, Marathon Digital Among Premarket Gainers' Pack
Seeking AlphaApr 8 09:10 ET
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announce
BenzingaApr 8 07:31 ET
Palatin Files to Sell 1.92M Shares of Common Stock for Holders
Seeking AlphaMar 14 16:30 ET
Palatin Technologies(PTN.US) Director Sells US$23,433.72 in Common Stocks
$Palatin Technologies(PTN.US)$ Director DEVEER ROBERT K JR sold 11,700 shares of Common Stocks on Mar 6, 2024 at an average price of $2.0029 for a total value of $23,433.72.Source: Announcement What i
moomoo NewsMar 7 17:45 ET
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
TipRanksFeb 29 07:56 ET
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were retreating late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) 0.7% lower. The iShares Biotechnology ETF (IBB)
MT NewswiresFeb 28 16:01 ET
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial
Palatin Technologies (PTN) shares were down about 37% in recent Wednesday trading after the company said a late-stage trial of its dry eye drug candidate, PL9643, did not achieve statistical significa
MT NewswiresFeb 28 14:25 ET
Palatin Technologies Is Maintained at Buy by HC Wainwright & Co.
Palatin Technologies Is Maintained at Buy by HC Wainwright & Co.
Dow JonesFeb 28 13:26 ET
Express News | HC Wainwright & Co. Maintains Buy on Palatin Techs, Adjusts Price Target To $17
Moomoo 24/7Feb 28 13:16 ET
Express News | Palatin Technologies Shares Are Trading Lower After the Company Announced Results for Its PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients With Dry Eye Disease Did Not Meet Co-primary Sign Endpoints and Secondary Sign Endpoints
Moomoo 24/7Feb 28 12:49 ET
Palatin Stock Plunges 40% on Mixed Phase 3 Data for Dry Eye Drug
Seeking AlphaFeb 28 10:14 ET
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)
TipRanksFeb 28 10:10 ET
Express News | Palatin Technologies Shared Resumed Trade
Moomoo 24/7Feb 28 09:44 ET
Express News | Palatin Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Down -40.8%
Moomoo 24/7Feb 28 09:36 ET
No Data
No Data